Knoll Capital Management, LP
Q1 2014 13F-HR Holdings
Net value change ($000)
-5,347
(-2.7%)
New positions
4
Sold out positions
1
Turnover %
2.5%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| AMPE | 4,372 | 30.3% |
| NWBO | 1,450 | NEW |
| TOVX | 1,441 | 70.2% |
| KERYX BIOPHARMACEUTICALS | 816 | 31.5% |
| GLMD | 746 | NEW |
| LUMOS PHARMA, INC. | 495 | 29.0% |
| NEPHROGENEX INC | 412 | NEW |
| MERRIMACK PHARMACEUTICALS IN | 409 | 102.3% |
| INO | 193 | 16.5% |
| CELSUS THERAPEUTICS PLC | 151 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| MEDIVATION | -11,802 | -7.4% |
| SEQUENOM INC | -2,073 | -100.0% |
| PARKERVISION INC | -670 | -73.6% |
| ADVAXIS INC | -241 | -25.4% |
| ECTE | -54 | -38.6% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|